Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin

NCT03009214 is registered in ClinicalTrials.gov with amcure GmbH as lead sponsor.

NCT NCT03009214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03009214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin
Lead sponsor
amcure GmbH
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2016
Completion date
May 7, 2021
Enrollment
55 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumor